NCT06850571View on ClinicalTrials.gov

Aflibercept and Bevacizumab for Diabetic Maculopathies

PHASE4RecruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Diabetic Maculopathy
Interventions
DRUG

Bevacizumab Injection [Avastin]

1.25 mg intravitreal injection given once monthly for three consecutive months.

DRUG

Aflibercept 2Mg/0.05Ml Inj,Oph

2.0 mg intravitreal injection given once monthly for three consecutive months.

Trial Locations (1)

10001

RECRUITING

Baghdad Medical City Complex, Baghdad

All Listed Sponsors
collaborator

Baghdad Medical City

OTHER

lead

Al-Mustansiriyah University

OTHER